Global Alzheimer's Disease Diagnostic Market Professional Survey Report 2019
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Alzheimer's Disease Diagnostic Quarterly Market Size Analysis
- 2.1 Alzheimer's Disease Diagnostic Business Impact Assessment - COVID-19
- 2.1.1 Global Alzheimer's Disease Diagnostic Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Alzheimer's Disease Diagnostic Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 By Players, Global Alzheimer's Disease Diagnostic Quarterly Market Size, 2019 VS 2020
- 3.2 By Players, Alzheimer's Disease Diagnostic Headquarters and Area Served
- 3.3 Date of Key Players Enter into Alzheimer's Disease Diagnostic Market
- 3.4 Key Players Alzheimer's Disease Diagnostic Product Offered
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Alzheimer's Disease Diagnostic Segments, By Type
- 4.1 Introduction
- 1.4.1 Genetic testing
- 1.4.2 Neurological exam
- 1.4.3 Mini-mental state exam (MMSE)
- 1.4.4 Brain imaging
- 1.4.5 Other
- 4.2 By Type, Global Alzheimer's Disease Diagnostic Market Size, 2019-2021
5 Impact of Covid-19 on Alzheimer's Disease Diagnostic Segments, By Application
- 5.1 Overview
- 5.5.1 Clinics
- 5.5.2 Hospitals
- 5.5.3 Diagnostic Centers
- 5.5.4 Other
- 5.2 By Application, Global Alzheimer's Disease Diagnostic Market Size, 2019-2021
- 5.2.1 By Application, Global Alzheimer's Disease Diagnostic Market Size by Application, 2019-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Eli Lilly
- 7.1.1 Eli Lilly Business Overview
- 7.1.2 Eli Lilly Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.1.3 Eli Lilly Alzheimer's Disease Diagnostic Product Introduction
- 7.1.4 Eli Lilly Response to COVID-19 and Related Developments
- 7.2 TauRx
- 7.2.1 TauRx Business Overview
- 7.2.2 TauRx Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.2.3 TauRx Alzheimer's Disease Diagnostic Product Introduction
- 7.2.4 TauRx Response to COVID-19 and Related Developments
- 7.3 Alector
- 7.3.1 Alector Business Overview
- 7.3.2 Alector Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.3.3 Alector Alzheimer's Disease Diagnostic Product Introduction
- 7.3.4 Alector Response to COVID-19 and Related Developments
- 7.4 Accera
- 7.4.1 Accera Business Overview
- 7.4.2 Accera Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.4.3 Accera Alzheimer's Disease Diagnostic Product Introduction
- 7.4.4 Accera Response to COVID-19 and Related Developments
- 7.5 Treventis
- 7.5.1 Treventis Business Overview
- 7.5.2 Treventis Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.5.3 Treventis Alzheimer's Disease Diagnostic Product Introduction
- 7.5.4 Treventis Response to COVID-19 and Related Developments
- 7.6 Neuro-Bio
- 7.6.1 Neuro-Bio Business Overview
- 7.6.2 Neuro-Bio Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.6.3 Neuro-Bio Alzheimer's Disease Diagnostic Product Introduction
- 7.6.4 Neuro-Bio Response to COVID-19 and Related Developments
- 7.7 Cognition Therapeutics
- 7.7.1 Cognition Therapeutics Business Overview
- 7.7.2 Cognition Therapeutics Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
- 7.7.3 Cognition Therapeutics Alzheimer's Disease Diagnostic Product Introduction
- 7.7.4 Cognition Therapeutics Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
- 9.1 About US
This report covers market size and forecasts of Alzheimer's Disease Diagnostic, including the following market information:
Global Alzheimer's Disease Diagnostic Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Alzheimer's Disease Diagnostic Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Alzheimer's Disease Diagnostic Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Alzheimer's Disease Diagnostic Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Eli Lilly, TauRx, Alector, Accera, Treventis, Neuro-Bio, Cognition Therapeutics, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Genetic testing
Neurological exam
Mini-mental state exam (MMSE)
Brain imaging
Other
Based on the Application:
Clinics
Hospitals
Diagnostic Centers
Other